Schrödinger teams up with MD Anderson on WEE1 inhibitor program; Amid JAK safety concerns, AbbVie touts new data for Rinvoq 

Physics-based discovery outfit Schrödinger and the University of Texas MD Anderson Cancer Center announced today a two-year research collaboration — focused on accelerating and optimizing development of Schrödinger’s investigational WEE1 inhibitor.

The team, made up of Schrödinger employees and researchers with  MD Anderson’s Translational Research to...

Click to view original post